Ab­b­Vie inks deal for Med­in­cell's long-act­ing in­jectable plat­form worth up to $1.9B

Ab­b­Vie is bet­ting more than $1.9 bil­lion on a French biotech’s long-act­ing in­jectable tech­nol­o­gy.

The deal gives Med­in­cell $35 mil­lion up­front and up to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.